Regulus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Updates

/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...

Related Keywords

United States ,San Diego ,California ,Morgan Carlson ,Edmund Lee ,Claire Padgett ,Rekha Garg ,Jay Hagan ,Regulus Therapeutics Inc ,Chronic Kidney Disease Drug Development Summit ,Program Updates ,Nasdaq ,Rnas The Company Or Regulus ,Clinical Development ,Exchange Commission ,Prnewswire Regulus Therapeutics Inc ,Development Rd Expenses ,Multiple Ascending Dose ,Autosomal Dominant Polycystic Kidney Disease ,Senior Vice President ,Vice President ,Genetic Cause ,Cash Equivalents ,Marketable Securities ,Dominant Polycystic Kidney Disease ,Private Securities Litigation Reform Act ,